MTD Mettler-Toledo International, Inc. Common Stock

Microsoft, Bloom Energy and Amgen highlight Zacks' latest market moves, with strong gains across Focus List, recommendation and dividend portfolios.

Mettler-Toledo International (MTD) is back in focus after fresh attention on its precision instruments business and diversified end markets, from pharmaceuticals to food manufacturing. Investors are reassessing the stock following this renewed spotlight. Recent trading has been lively for Mettler-Toledo International, with the share price climbing 20.08% over the past 90 days and 8.08% across the last month. The 1-year total shareholder return of 25.51% and 3-year total shareholder return of...

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.

Weitz Investment Management, an investment management firm, released its second-quarter Q2 2026 investor letter for the “Multi Cap Equity Fund”. The letter can be downloaded here. The Multi Cap Equity Fund’s Institutional Class returned 7.90% in Q2, underperforming the Bloomberg U.S. 3000 Index’s 15.71% gain. Markets rose in the quarter on hopes of de-escalating Middle East […]

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.

Mettler-Toledo has lagged behind the Nasdaq Composite over the past year, and analysts remain moderately bullish about the stock’s outlook.

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the research tools & consumables industry, including Mettler-Toledo (NYSE:MTD) and its peers.

Investing.com -- Mettler-Toledo faces a growing mismatch between its premium valuation and a more modest growth outlook as competition intensifies across its weighing and laboratory businesses, brokerage Redburn said on Wednesday, initiating coverage of the precision-instrument maker with a Sell rating.

Mettler-Toledo has underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects.

Mettler-Toledo (MTD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 27.5% gain over the past six months, beating the S&P 500 by 16.2 percentage points.

Bank of America, Mettler-Toledo and VSE post strong gains as Zacks' Focus List, ECAP and Top 10 picks outperform.

This exercise-and-sell transaction captured a gain on options struck at $397.95.

Head of Process Analytics Gerry Keller liquidated stock worth $342,514 on August 3.

Salice exercised 415 stock options at $397.95 and immediately sold them at $1,444.62.

Vadala exercised stock options and liquidated the position same-day.

Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.

China sales surged 9% as laboratory demand accelerated, lifting full-year guidance.

Mettler-Toledo International Inc. recently reported second-quarter 2026 results showing higher sales of US$1,027.31 million and net income of US$232.90 million, while also appointing MISTRAS Group CEO Natalia Shuman to its Board of Directors effective 3 August 2026. Together with Baron Capital’s decision to increase its long-held position after a recent pullback, these developments point to growing institutional engagement and fresh governance expertise focused on technology-enabled services...

Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]

MTD beats Q2 earnings estimates as strong China and emerging-market sales fuel growth, while the company raises its 2026 sales and earnings outlook.

Credo Technology leads Zacks' latest market-beating highlights as strong stock gains and portfolio performance stand out despite a mixed U.S. economy.

While the top- and bottom-line numbers for Mettler-Toledo (MTD) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Mettler-Toledo International (NYSE:MTD) reported second-quarter results that exceeded its prior sales-growth expectations, supported by improving market conditions, particularly in China and other emerging markets, as well as its sales and marketing initiatives. Chief Executive Officer Patrick Kalt

Mettler-Toledo International Inc (MTD) beats expectations with 4% organic sales growth, led by China and emerging markets, while raising full-year EPS guidance to $47.15-$47.50.

Moby summary of Mettler-Toledo International Inc.'s Q2 2026 earnings call

Mettler-Toledo (MTD) delivered earnings and revenue surprises of +6.31% and -0.46%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Precision measurement company Mettler-Toledo (NYSE:MTD) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 4.5% year on year to $1.03 billion. Its non-GAAP profit of $11.46 per share was 6.1% above analysts’ consensus estimates.

Precision measurement company Mettler-Toledo (NYSE:MTD) will be reporting results this Thursday afternoon. Here’s what to expect.

Besides Wall Street's top-and-bottom-line estimates for Mettler-Toledo (MTD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.

Mettler-Toledo (MTD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Mettler-Toledo (MTD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.